Vienna - Delayed Quote EUR
Pharma Mar, S.A. (PHM.VI)
81.30
+1.45
+(1.82%)
At close: 3:30:16 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
174,855
174,855
158,153
196,343
229,831
Cost of Revenue
8,183
8,183
9,613
13,639
16,437
Gross Profit
166,672
166,672
148,540
182,704
213,394
Operating Expense
160,370
160,370
152,638
138,269
121,043
Operating Income
6,302
6,302
-4,098
44,435
92,351
Net Non Operating Interest Income Expense
3,196
3,196
1,687
-1,501
-3,003
Pretax Income
11,985
11,985
-3,623
43,790
95,129
Tax Provision
-14,140
-14,140
-4,760
-5,566
2,270
Net Income Common Stockholders
26,125
26,125
1,137
49,356
92,859
Diluted NI Available to Com Stockholders
26,125
26,125
1,137
49,356
92,859
Basic EPS
1.49
1.49
0.06
2.73
5.14
Diluted EPS
1.49
1.49
0.06
2.73
5.13
Basic Average Shares
17,539
17,539
17,900
18,050
18,070
Diluted Average Shares
17,562
17,562
17,916
18,063
18,085
Total Operating Income as Reported
6,468
6,468
-3,827
44,071
92,447
Rent Expense Supplemental
--
--
1,646
1,675
--
Total Expenses
168,553
168,553
162,251
151,908
137,480
Net Income from Continuing & Discontinued Operation
26,125
26,125
1,137
49,356
92,859
Normalized Income
25,989.25
25,989.25
783
51,045
92,754.55
Interest Income
5,665
5,665
4,103
875
370
Interest Expense
2,469
2,469
2,416
2,376
3,373
Net Interest Income
3,196
3,196
1,687
-1,501
-3,003
EBIT
14,454
14,454
-1,207
46,166
98,502
EBITDA
21,227
21,227
4,549
52,066
104,085
Reconciled Cost of Revenue
8,183
8,183
9,613
13,639
16,437
Reconciled Depreciation
6,773
6,773
5,756
5,900
5,583
Net Income from Continuing Operation Net Minority Interest
26,125
26,125
1,137
49,356
92,859
Total Unusual Items Excluding Goodwill
181
181
472
-2,252
107
Total Unusual Items
181
181
472
-2,252
107
Normalized EBITDA
21,046
21,046
4,077
54,318
103,978
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
45.25
45.25
118
-563
2.55
12/31/2021 - 12/27/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
8E8.MU Elicera Therapeutics AB
0.3040
0.00%
ARGX.VI argenx SE
530.20
+0.88%
PHVS Pharvaris N.V.
15.83
+6.82%
MSCL.TO Satellos Bioscience Inc.
0.6600
+6.45%
STTK Shattuck Labs, Inc.
0.8379
-1.57%
BION.SW BB Biotech AG
28.25
-0.70%
PVLA Palvella Therapeutics, Inc.
25.47
-4.10%
ONC BeiGene, Ltd.
256.16
+2.82%
CLSD Clearside Biomedical, Inc.
0.8485
+6.66%
UCB.BR UCB SA
147.35
+0.41%